Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference15 articles.
1. COVID-19: consider cytokine storm syndromes and immunosuppression;Mehta;Lancet,2020
2. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis;Lancet,2022
3. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease;Richardson;Lancet,2020
4. COVID-19: combining antiviral and anti-inflammatory treatments;Stebbing;Lancet Infect Dis,2020
5. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial;Group;Lancet,2021
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. WHO declares end of mpox global health emergency: first glance from a perspective of ChatGPT/GPT-4;International Journal of Surgery;2023-06-19
2. Potential Use of Artificial Intelligence in Infectious Disease: Take ChatGPT as an Example;Annals of Biomedical Engineering;2023-04-19
3. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review;Frontiers in Pharmacology;2023-03-20
4. Effect of Il-6/Il-10 Ratio on 28-Day Mortality and Dosage of Corticosteroid Therapy in Severe Covid-19;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3